Literature DB >> 28158421

Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial.

Yohei Sotomi1, Yoshinobu Onuma2,3, Jouke Dijkstra4, Yosuke Miyazaki2, Ken Kozuma5, Kengo Tanabe6, Jeffrey J Popma7, Robbert J de Winter1, Patrick W Serruys8, Takeshi Kimura9.   

Abstract

Aims: The natural course of post-procedural incomplete strut apposition (ISA) after the implantation of bioresorbable scaffolds (BVS) remains unknown. The purpose of the present study was to evaluate the fate of post-procedural ISA after everolimus-eluting Absorb BVS in comparison with the second-generation everolimus-eluting cobalt chromium stent (CoCr-EES). Methods and results: Fate of post-procedural ISA was evaluated by serial optical coherence tomography (OCT) in the ABSORB Japan randomized trial [OCT-1 subgroup: 110 paired lesions of post-procedure and 2-year follow-up (BVS 73 lesions vs. CoCr-EES 37 lesions)] with respect to ISA distance. Post-procedure ISA struts were categorized into either 'resolved' or 'persistent' by matched OCT imaging at 2-year follow-up. Post-procedure %malapposed strut and ISA area were smaller in BVS than in CoCr-EES (%malapposed strut: 4.8 ± 6.9% vs. 9.9 ± 9.8%, P = 0.002; ISA area 0.10 ± 0.18 mm2 vs. 0.23 ± 0.26 mm2, P = 0.003). At 2-year follow-up, the difference diminished, and majority of the ISA struts spontaneously resolved in both arms (%malapposed strut: 0.10 ± 0.46% vs. 0.24 ± 0.65%, P = 0.183). Receiver operating characteristic curve analysis (BVS 661 struts vs. CoCr-EES 807 struts) demonstrated that the best cut-off value of endoluminal ISA distance post-procedure for predicting persistent-ISA at 2-year follow-up was 396 µm for BVS (sensitivity 0.875; specificity 0.851) and 359 µm for CoCr-EES (sensitivity 0.778; specificity 0.881).
Conclusion: BVS as compared with CoCr-EES allows larger ISA distance at post-procedure, although we should make every effort to minimize post-procedure ISA. The reported cut-off value of OCT-estimated ISA distance at post-stenting for predicting persistent-ISA would be helpful to optimize PCI with BVS and CoCr-EES. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  bioresorbable scaffold ; metallic stent ; optical coherence tomography ; randomized controlled trial; strut malapposition

Mesh:

Substances:

Year:  2018        PMID: 28158421     DOI: 10.1093/ehjci/jew329

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  5 in total

Review 1.  Optical Coherence Tomography: An Eye Into the Coronary Artery.

Authors:  Ankush Gupta; Abhinav Shrivastava; Rajesh Vijayvergiya; Sanya Chhikara; Rajat Datta; Atiya Aziz; Daulat Singh Meena; Ranjit Kumar Nath; J Ratheesh Kumar
Journal:  Front Cardiovasc Med       Date:  2022-05-11

2.  Synergistic mechanism of coincidence of two subacute stent thromboses: Insights from multiple imaging observations.

Authors:  Tadakiyo Ido; Yohei Sotomi; Yasuhiro Ichibori; Yasunori Ueda; Yoshiharu Higuchi
Journal:  J Cardiol Cases       Date:  2021-04-15

Review 3.  Optical Coherence Tomography of the Coronary Arteries.

Authors:  Robert Roland; Josef Veselka
Journal:  Int J Angiol       Date:  2021-02-12

4.  Severe Acute Stent Malapposition After Drug-Eluting Stent Implantation: Effects on Long-Term Clinical Outcomes.

Authors:  Seung-Yul Lee; Eui Im; Sung-Jin Hong; Chul-Min Ahn; Jung-Sun Kim; Byeong-Keuk Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

Review 5.  Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management.

Authors:  Amr Abouelnour; Tommaso Gori
Journal:  Front Cardiovasc Med       Date:  2022-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.